SCHEMBL2655862

SCHEMBL2655862

FC(F)(F)Oc1ccc(-c2cccc(Cl)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.51
TAAR1 Q96RJ0 2/20 0.49
SCN5A Q14524 1/20 0.48
TRPV1 Q8NER1 1/20 0.46
ALOX5 P09917 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
CCR6 P51684 5/20 0.45
KCNH2 Q12809 3/20 0.45
MAOB P27338 2/20 0.45
PDK2 Q15119 1/20 0.43
DHODH Q02127 1/20 0.43
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
ESR2 Q92731 1/20 0.42
AURKA O14965 1/20 0.42
TPX2 Q9ULW0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628993 0.87 SCN5A (0.54) SCN5AAKR1C2AKR1C1CA12CA9
SCHEMBL10059900 0.80 PDE10A (0.51) GRIN2BSCN5ATRPV1CCR6KCNH2
SCHEMBL255377 0.79 P2RX1 (0.50) GRIN2BTRPV1CCR6KCNH2
SCHEMBL29893341 0.79 P2RX1 (0.50) GRIN2BTRPV1CCR6KCNH2
SCHEMBL30363971 0.79 ABL1 (0.54) TAAR1SCN5ACA12CA9AURKA
SCHEMBL1241524 0.79 ABL1 (0.54) TAAR1SCN5ACA12CA9AURKA
SCHEMBL1029424 0.79 HSD17B1 (0.61) SCN5AAKR1C2AKR1C1ESR2AURKA
SCHEMBL5544095 0.79 SCN5A (0.48) SCN5AAKR1C2AKR1C1DHODHCA12
SCHEMBL5544105 0.79 SCN5A (0.48) SCN5APDK2CA12CA9AURKA
SCHEMBL18293362 0.78 KIF11 (0.50) GRIN2BSCN5AAKR1C2AKR1C1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318760-B2 Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-07-03 US disclosed
EP-1863755-A1 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES Merck & Co., Inc. (US) 2007-12-12 EP disclosed
WO-2006102067-A1 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES MERCK & CO., INC. (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use GPR119, PNLIP, SLC5A2 GRIN2B 1964/4885TAAR1 3231/4885SCN5A 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.